
Join to view full profile
8000 Ravines Edge CtSte 200Columbus, OH 43235
Phone+1 614-304-3444
Fax+1 614-304-3433
Dr. Boster is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MichiganResidency, Neurology, 2003 - 2006
University of MichiganInternship, Internal Medicine, 2002 - 2003
University of Cincinnati College of MedicineClass of 2002
Certifications & Licensure
MI State Medical License 2005 - 2029
WV State Medical License 2023 - 2028
IN State Medical License 2023 - 2027
KY State Medical License 2023 - 2027
OH State Medical License 2008 - 2027
TN State Medical License 2023 - 2027
TX State Medical License 2023 - 2027
American Board of Psychiatry and Neurology Neurology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2017
- CMS Meaningful Use Stage 2 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2012, 2014, 2017
Clinical Trials
Publications & Presentations
PubMed
- The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosis.Delphine Van Laethem, Lars Costers, Augusto Miravalle, Enrique Alvarez, Bennett Myers
Scientific Reports. 2026-05-16 - 61 citationsToward Precision Phenotyping of Multiple Sclerosis.David Pitt, Chih Hung Lo, Susan A Gauthier, Richard A Hickman, Erin Longbrake
Neurology(R) Neuroimmunology & Neuroinflammation. 2022-11-01 - 20 citationsAutoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass
Multiple Sclerosis. 2022-04-01
Press Mentions
- Diagnosing MS During a Pandemic: UK vs. USOctober 23rd, 2020
Neurologists Turn to Telemedicine During Coronavirus ShelteringApril 3rd, 2020
Hospital Plots Leadership Path in MS ResearchSeptember 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:













